Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6228906 | 0.85 | TDP1 (0.36) | HSD17B10ALOX15ALOX12TDP1CYP3A4 | |
| SCHEMBL301662 | 0.70 | HSD17B10 (0.59) | HSD17B10ALOX15ALOX12TDP1CYP3A4 | |
| SCHEMBL28049518 | 0.70 | TSHR (0.36) | HSD17B10ALOX15ALOX12TDP1CYP3A4 | |
| SCHEMBL3803700 | 0.69 | TDP1 (0.45) | HSD17B10ALOX15ALOX12TDP1CYP3A4 | |
| SCHEMBL94118 | 0.69 | KLK1 (0.45) | HSD17B10ALOX15ALOX12TDP1CYP3A4 | |
| SCHEMBL11451272 | 0.69 | TSHR (0.39) | HSD17B10ALOX15ALOX12TDP1CYP3A4 | |
| SCHEMBL7119836 | 0.68 | HSD17B10 (0.52) | HSD17B10ALOX15ALOX12TDP1CYP3A4 | |
| SCHEMBL27503034 | 0.67 | TSHR (0.43) | HSD17B10ALOX15ALOX12TDP1CYP3A4 | |
| SCHEMBL6285005 | 0.67 | MEN1 (0.55) | HSD17B10ALOX15ALOX12TDP1CYP3A4 | |
| SCHEMBL9240974 | 0.67 | KLK1 (0.53) | TDP1CYP3A4TSHRALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6103891-A | Method for the synthesis of nucleotide or oligonucleotide phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-15 | — | — | US | claimed |
| JP-63222187-A | — | — | None | — | — | JP | disclosed |
| EP-0948514-B1 | METHOD FOR THE SYNTHESIS OF NUCLEOTIDE OR OLIGONUCLEOTIDE PHOSPHORAMIDITES | ISIS PHARMACEUTICALS INC (US) | 2005-04-27 | — | — | EP | disclosed |
| EP-0885237-B1 | OLIGONUCLEOTIDE ANALOGUES | ISIS PHARMACEUTICALS INC (US) | 2003-09-10 | — | — | EP | disclosed |
| US-6562960-B1 | Oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-20030013864-A1 | Method for the synthesis of nucleotide of oligonucleotide phosphoramidites | GRIFFEY RICHARD H (US) | 2003-01-16 | — | — | US | disclosed |
| US-6458941-B1 | RECOVERED FROM WASTE PRODUCTS OF OLIGONUCLEOTIDE BIOSYNTHESIS | ISIS PHARMACEUTICALS, INC. | 2002-10-01 | — | — | US | disclosed |
| US-6441150-B1 | GENETIC ENGINEERING | ISIS PHARMACEUTICALS, INC. | 2002-08-27 | — | — | US | disclosed |
| EP-0948514-A4 | METHOD FOR THE SYNTHESIS OF NUCLEOTIDE OR OLIGONUCLEOTIDE PHOSPHORAMIDITES | ISIS PHARMACEUTICALS INC (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6140310-A | ADMINISTERING AN EFFECTIVE AMOUNT OF PHOSPHORUS PRODRUG IN A MAMMAL FOR TREATING A VIRAL INFECTION | DRUG INNOVATION & DESIGN, INC. (US) | 2000-10-31 | — | — | US | disclosed |
| US-5955600-A | Method for the synthesis of nucleotide or oligonucleotide phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-21 | — | — | US | disclosed |
| EP-0885237-A1 | OLIGONUCLEOTIDE ANALOGUES | Novartis AG (CH) | 1998-12-23 | — | — | EP | disclosed |
| US-5789608-A | LIPID SOLUBLE; DIFFUSE INTO CELLS AND TISSUE; VIRICIDES, ANTICANCER AGENTS | DRUG INNOVATION AND DESIGN, INC. (US) | 1998-08-04 | — | — | US | disclosed |
| WO-1998029429-A1 | METHOD FOR THE SYNTHESIS OF NUCLEOTIDE OR OLIGONUCLEOTIDE PHOSPHORAMIDITES | ISIS PHARMACEUTICALS, INC. (US) | 1998-07-09 | — | — | WO | disclosed |
| WO-1997032887-A1 | OLIGONUCLEOTIDE ANALOGUES | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | disclosed |
| US-5627165-A | ANTIVIRAL AND ANTILEUKEMIA AGENTS | DRUG INNOVATION & DESIGN, INC. (US) | 1997-05-06 | — | — | US | disclosed |
| EP-0533833-B1 | PHOSPHOROUS PRODUGS | GLAZIER ARNOLD (US) | 1995-12-20 | — | — | EP | disclosed |
| EP-0533833-A1 | PHOSPHOROUS PRODRUGS. | GLAZIER ARNOLD (US) | 1993-03-31 | — | — | EP | disclosed |
| WO-1991019721-A1 | PHOSPHOROUS PRODUGS | GLAZIER ARNOLD (US) | 1991-12-26 | — | — | WO | disclosed |
| JP-S63222187-A | CONDENSING AGENT FOR FORMING PHOSPHORIC ACID ESTER AND USAGE THEREOF | TOA NENRYO KOGYO KK | 1988-09-16 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013864-A1 | Method for the synthesis of nucleotide of oligonucleotide phosphoramidites | NUDT1, MTAP, PHOSPHO1 | HSD17B10 1977/4885ALOX15 1581/4885ALOX12 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.